Diversified model, US outlook to help Dr Reddy's stock trade better

Dr Reddy’s Laboratories stock has gained more than 50 per cent from its March lows and is trading close to its four-year highs. Investor confidence in the drugmaker’s prospects not only stems from expectations of strong growth in India, but also from improving prospects in the US operations. In fact, analysts are of the opinion that the stock price is not completely factoring in the upside from the US business. Hence, there is more upside in the stock from current levels.

The company has been changing its focus from regulated markets to India and other emerging markets such as China. For